Name

Pharmicell

Legal name

Pharmicell Co., Ltd. (주)파미셀

Website

https://pharmicell.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Stem cell therapy
• Pharmaceutical ingredients
• Cell culture media
• Biopharmaceutical manufacturing
• Stem cell cosmetics

Headquarters

HQ city

Yeoksamdong

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Stem Cell Therapy Products: Commercialized stem cell therapy products including Hearticellgram-AMI (approved 2011) and pipeline products in clinical trials. Revenue from product sales to hospitals and clinics. Additional revenue from clinical development partnerships and potential technology licensing.
2. Bio-chemicals (APIs and Intermediates): Supply of active pharmaceutical ingredients including nucleosides and mPEG to global pharmaceutical companies. Nucleosides used in gene therapy drugs and diagnostic reagents. mPEG used in pegylation drug delivery technology. Products supplied to Pfizer, Moderna, Roche, Merck, and others.
3. Cosmetics (By Pharmicell Lab): Stem cell culture media-based cosmetic products sold under By Pharmicell Lab brand. Includes skincare, hair care, and professional-use products. Distribution through professional aesthetic channels and home shopping.
4. Stem Cell Banking Services: Stem cell preservation and storage services for future medical use.
5. CDMO Services: Contract manufacturing and development services for cell therapy products and related research.
6. Low-dielectric Electronic Materials: Specialty electronic materials for AI accelerators, 5G equipment, and semiconductor applications. Supplied to major electronics manufacturers.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Pharmicell is a South Korean biopharmaceutical company operating two divisions. The Biomedical division develops and sells stem cell therapies (Hearticellgram-AMI for acute myocardial infarction, plus pipeline products Cellgram-LC, Cellgram-ED, Cellgram-CKD, Cellgram-DC), stem cell culture media (Half-Serum DMEM, PharmiSTEM hMSC Media), CDMO services, stem cell banking, and stem cell-conditioned media cosmetics under By Pharmicell Lab and Play Cell brands. The Biochemical division manufactures active pharmaceutical ingredients including nucleosides and mPEG (methoxypolyethylene glycol), low-dielectric electronic materials for AI accelerators/5G, and organophosphorus flame retardants.

Product overview

Pharmicell is a biopharmaceutical company operating two main business divisions: Biomedical (stem cell-based) and Biochemical (chemical-based). The Biomedical division focuses on stem cell therapy products including the world's first approved Hearticellgram®-AMI for acute myocardial infarction, and pipeline products like Cellgram-LC (liver cirrhosis), Cellgram-ED (erectile dysfunction), Cellgram-CKD (chronic kidney disease), Cellgram-DC (cancer immunotherapy), and various investigational therapies. The division also includes stem cell culture media products (Half-Serum™ DMEM, PharmiSTEM™ hMSC Media), cosmetics brands (By Pharmicell Lab, Play Cell), and stem cell banking services. The Biochemical division produces active pharmaceutical ingredients (nucleosides, mPEG), low-dielectric electronic materials for AI/semiconductor applications, and flame retardants. Recent product launches include the BM SOME 200 professional skincare/haircare line featuring proprietary bone marrow stem cell conditioned media liposome technology at 20% concentration.

Differentiator

Problem solved

Functional benefit

Brands

• By Pharmicell LAB (바이 파미셀 랩): Premium derma-cosmetics brand featuring human bone marrow-derived stem cell conditioned media liposome technology
• Play Cell (플레이 셀)

Products and services

• Hearticellgram-AMI World's first approved stem cell therapy product for acute myocardial infarction (AMI), using autologous bone marrow-derived mesenchymal stem cells administered via intracoronary injection in 10ml, 14ml, and 18ml doses. Sold to hospitals including Severance Hospital and 9 other institutions (135 patients cumulative).
• Cellgram-LC Stem cell therapy product for alcoholic liver cirrhosis using bone marrow-derived mesenchymal stem cells, currently in Phase 3 clinical trial at 8 institutions with 200-patient target.
• Cellgram-ED Stem cell therapy for erectile dysfunction administered via intracavernosal injection. Phase 2 clinical trial approved at Seoul Asan Hospital with 54-patient target.
• Cellgram-CKD Stem cell therapy for chronic kidney disease. Phase 1 clinical trial approved at Seoul Asan Hospital with 10-patient target.
• Cellgram-SCI Stem cell therapy for spinal cord injury, administered intrathecally. Published research in Neurosurgery journal demonstrating nerve regeneration effects.
• Cellgram-IS Stem cell therapy for cerebral infarction (ischemic stroke), administered intravenously to improve activities of daily living and reduce disability.
• Cellgram-CLI Stem cell therapy for critical limb ischemia, administered via intramuscular injection to patients at risk of amputation.
• Cellgram-DC Cancer immunotherapy vaccine using dendritic cells educated with tumor antigens, derived from bone marrow hematopoietic stem cells. Aims to induce tumor-specific immune response with minimal side effects.
• Half-Serum DMEM Proprietary cell culture medium developed by Pharmicell's R&D for stem cell research applications.
• PharmiSTEM hMSC Media Human mesenchymal stem cell (hMSC) culture medium for research and commercial applications.
• CDMO Services Contract development and manufacturing organization services for cell therapy products, including quality control outsourcing and GMP facility access.
• Stem Cell Banking (Twelve) Stem cell storage and banking service for preserving healthy stem cells for future medical use, with 15-year storage options offered directly to consumers.
• Nucleosides and mPEG Active pharmaceutical ingredients including nucleosides for gene therapy and diagnostic reagents, and mPEG (methoxypolyethylene glycol) for drug delivery pegylation technology. Supplied to Pfizer, Moderna, Merck, Roche, Thermo Fisher, Nektar Therapeutics, UCB, and Baxter International.
• Low-Dielectric Electronic Materials Specialty chemical products including ultra-low dielectric materials used in semiconductors and electronic components for AI accelerators, 5G network equipment, and base station antennas. Supplied to companies like Doosan Electronics (which in turn supplies Cisco).
• Flame Retardants Organophosphorus flame retardants for polymer materials used in mobile PCB, automotive interiors, and textiles. Supplied to global flame retardant companies including Germany's Trevira (world's No. 1 flame retardant company).
• BM SOME 200 Professional Line Premium professional derma-cosmetic line under By Pharmicell Lab featuring BM SOME liposome technology at 20% concentration, including BM SOME 200 Ampoule for skin care and BM SOME 200 Rootive Hair Ampoule for scalp and hair care used in professional MTS treatments.
• Vita Ampoule Flagship By Pharmicell Lab ampoule cosmetic product renewed with 18% pure vitamin content and 3% bone marrow stem cell conditioned media liposome (BM SOME).
• Rootive Hair Shampoo Home care hair product in the BM SOME 200 professional line, designed for scalp and hair care maintenance.
• Rootive Hair Scalp Serum Home care scalp treatment product in the BM SOME 200 professional line for scalp care and maintenance.

Quantifiable outcome

• World's first stem cell therapy product approved (Hearticellgram-AMI, 2011)
• +3 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Yonsei University Wonju College of Medicine (연세대학교 원주의과대학)coreStrategic or Co-development Partner · 8 May 2026Joint research collaboration for regenerative medicine and cell therapy. Conducted preclinical studies on allogeneic bone marrow-derived mesenchymal stem cells (BM-MSC) for severe alcoholic hepatitis treatment. Research results published in international journal Gut and Liver.
• Wonju Severance Christian Hospital (원주연세의료원)coreStrategic or Co-development Partner · 8 May 2026Co-hosted Regenerative Medicine Symposium with research presentations on stem cell therapy, exosome technology, and AI applications in cell therapy. Ongoing joint research programs and clinical trials.
• Trevira GmbH (Germany)coreTechnology or IntegrationExclusive supplier of flame retardant materials to Trevira, the world's No. 1 flame retardant company. Partnership established after 4 years of persuasion efforts, successfully displacing US competitors.

Scale indicators15 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Celltrion: Korean biopharmaceutical company developing biosimilars and novel biologics. Direct peer to Pharmicell as a publicly-traded Korean biotech with operations in specialty pharmaceutical manufacturing and growing international presence.
• Mesoblast: Australia-listed cell therapy company developing allogeneic mesenchymal stem cell therapies including revascor for cardiovascular indications (chronic heart failure). Direct stem cell therapy peer competing with Pharmicell's Hearticellgram-AMI franchise.
• Athersys: US-based clinical-stage cell therapy company developing MultiStem, an allogeneic stem cell platform for inflammatory, immune-mediated, cardiovascular and neurological conditions. Direct stem cell therapy competitor to Pharmicell's Cellgram pipeline.
• Pluristem Therapeutics: Israel-based company developing placenta-derived allogeneic cell therapies. Direct peer in regenerative cell therapy space; relevant as a competitor evaluating allogeneic scalability vs Pharmicell's autologous workflow.

Broad incumbents

• Samsung Biologics: Korea's largest biopharmaceutical CDMO with end-to-end contract development and manufacturing capabilities. Direct peer to Pharmicell's CDMO services division and broader biologics manufacturing footprint.
• WuXi AppTec: Global CRO/CDMO providing cell therapy development services, API manufacturing, and biologics testing. Direct peer to Pharmicell's CDMO services and competing nucleoside/API supply capability.
• Lonza Group: Global leader in cell and gene therapy CDMO services offering GMP manufacturing for autologous and allogeneic cell therapies. Direct peer to Pharmicell's CDMO services for cell therapy products and related contract manufacturing.

Regional players

• Amorepacific: Korea's largest cosmetics company with biotech-derived skincare lines. Peer to Pharmicell's By Pharmicell Lab cosmetics business in the premium derma-cosmetics channel using proprietary stem cell conditioned media technology.
• Hanmi Pharmaceutical: Major Korean pharmaceutical company developing branded innovative drugs across cardiometabolic, oncology, and immunology. Direct peer as a Korean pharma with branded specialty pharmaceutical pipeline exposure.
• SK Bioscience: Korean vaccine and biotech company with cell culture-based biomanufacturing capabilities. Peer to Pharmicell's biologics manufacturing infrastructure and vaccine-relevant stem cell applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmicell-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmicell